OncLive TV

R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.

Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.

Corinne Faivre-Finn, MD, discusses ongoing clinical debates regarding patient selection and optimal delivery of concurrent chemoradiotherapy followed by immunotherapy in LS-SCLC.

Shilpa Gupta, MD, discusses the clinical effects of findings from the phase 3 EV-302/KEYNOTE-A39 trial in locally advanced/metastatic urothelial carcinoma.

Xiuning Le, MD, PhD, discusses efficacy data with firmonertinib for the treatment of patients with EGFR PACC–mutated NSCLC.

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Emil Lou, MD, PhD, FACP, discusses the rationale for evaluating CISH knockout TILs using CRISPR-Cas9 gene editing in metastatic GI cancers.

[The baseline patient population] represents what we see in the real world, with a median age of 73. [This] is older than what we see in [many] clinical trials.

Martin Dreyling, MD, discusses prior findings and potential implications of the phase 3 ECHO trial of acalabrutinib plus BR in pretreated MCL.

Sarah Lynam, MD, highlights the importance of folate receptor–alpha expression testing to inform treatment decision-making in patients with ovarian cancer.

Percy Lee, MD, discusses the importance of considering radiation therapy techniques like IMRT and proton therapy for patients with locally advanced NSCLC.

Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.

Tarek Mouhieddine, MD, discusses the use of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory multiple myeloma.

Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.

Randy F. Sweis, MD, explains the mechanism of action of the ENPP3/CD3–targeted bispecific T-cell engager XmAb819 in renal cell carcinoma.

Kevin Elias, MD, discusses the SOLO-1 and SOLO-2 trials, which evaluated olaparib in newly diagnosed and relapsed BRCA-mutated ovarian cancer.

R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.

Martin Dreyling, MD, discusses why adding acalabrutinib to bendamustine plus rituximab may benefit patients with pretreated, high-risk MCL.

Fred Saad, MD, discusses the rationale behind the long-term safety analysis for radium-223 dichloride and enzalutamide in metastatic castration-resistant prostate cancer with bone-predominant disease.

Sarah Lynam, MD, discusses the significance and implications of mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.

Sagus Sampath, MD, discusses the safety profile of consolidative radiotherapy administered in conjunction with osimertinib in advanced EGFR-mutant NSCLC

Luqui Qiu, MD, discusses the efficacy and safety of eque-cel in patients with relapsed or refractory multiple myeloma.

Tarek Mouhieddine, MD, discusses the background and design of a study of correlates of response to bispecific antibodies in relapsed/refractory myeloma.

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.

Andrew Yee, MD, discusses lenalidomide plus ixazomib,​ dexamethasone, and daratumumab in newly diagnosed multiple myeloma.

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

Alexis LeVee, MD, discusses the clinical implications of the ASCENT-04 trial data for patients with TNBC who relapse following prior PD-1 or PD-L1 therapy.

Karie Runcie, MD, discusses the mechanism of action of XmAb30819 in clear cell RCC.